<span item_type="fundamental" item_id="fc0060f2c6c2cee0f8904fdb6abc395b" counter_id="ST/US/IBRX" env="prod"></span><span item_type="announcement" item_id="579384167545574401" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 32.06 M, beating the estimate of USD 31.88 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.07, beating the estimate of USD -0.108.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -30.11 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Total Revenue and Other Income</strong>: $33.7 million in Q3 2025, up from $26.4 million in Q2 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326110/000132611025000138/ibrx-2025114x8kexhibit991.htm"></span></li><li><strong>Product Revenue</strong>: $31.8 million in Q3 2025, a 434% increase from $6.0 million in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326110/000132611025000138/ibrx-2025114x8kexhibit991.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: $67.3 million in Q3 2025, compared to $85.7 million in Q3 2024, showing a reduction in loss.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326110/000132611025000138/ibrx-2025114x8kexhibit991.htm"></span></li><li><strong>Research and Development Expense</strong>: Increased by $0.8 million to $51.2 million in Q3 2025 from $50.4 million in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326110/000132611025000138/ibrx-2025114x8kexhibit991.htm"></span></li><li><strong>Selling, General and Administrative Expense</strong>: Increased by $0.4 million to $36.3 million in Q3 2025 from $35.9 million in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326110/000132611025000138/ibrx-2025114x8kexhibit991.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Cash Position</strong>: $257.8 million in cash, cash equivalents, and marketable securities as of September 30, 2025, up from $153.7 million as of June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326110/000132611025000138/ibrx-2025114x8kexhibit991.htm"></span></li><li><strong>Net Cash Used in Operating Activities</strong>: - $68.9 million in Q3 2025, compared to - $98.8 million in Q3 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326110/000132611025000138/ibrx-2025114x8kexhibit991.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>ANKTIVA Unit Growth</strong>: 467% unit sales volume growth year-to-date 2025 compared to fiscal year 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326110/000132611025000138/ibrx-2025114x8kexhibit991.htm"></span></li></ul><h3>Outlook / Guidance</h3><p>ImmunityBio anticipates continued strong demand for ANKTIVA, with plans to expand its reach to a broader population of bladder cancer patients. The company is optimistic about the potential growth opportunities for its science and its ability to address unmet needs in cancer treatment.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1326110/000132611025000138/ibrx-2025114x8kexhibit991.htm"></span></p>

ImmunityBio | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 32.06 M